Lenalidomide: a new treatment option for Castleman disease-Reference-Cited by-同舟云学术

Lenalidomide: a new treatment option for Castleman disease

Published:2011-12-05 Issue:10 Volume:53 Page:2089-2091
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Szturz Petr,Adam Zdeněk,Chovancová Jana,Stehlíková Olga,Klabusay Martin,Řehák Zdeněk,Koukalová Renata,Krejčí Marta,Pour Luděk,Zahradová Lenka,Hájek Roman,Mayer Jiří

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.621564

Reference15 articles.

1. Case 40351

2. A retrospective study of unicentric and multicentric Castleman’s disease: a report of 52 patients

3. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care

4. Giant lymph node hyperplasia (castleman's disease) with spontaneous production of high levels of b-cell differentiation factor activity

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicentric Castleman's disease. Symptoms, diagnostics and therapy;Vnitřní lékařství;2022-02-14

2. Treatment response and prognosis of POEMS syndrome coexisting with Castleman disease;Journal of the Neurological Sciences;2020-06

3. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases: a 10-year retrospective study;Journal of Cancer Research and Clinical Oncology;2020-01-14

4. Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids;Medicine;2019-11

5. Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases;Frontiers of Medicine;2017-04-03